Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
LRF by KRAS and assigned treatment. Rates of local failure based on treatment and KRAS-variant status, with KRAS-variant patients being depicted by blue lines and nonvariant patients by red lines and dashed lines representing cetuximab-treated patients.
Fields of Study & Subjects
Head and Neck Cancer Studies
Esophageal Cancer Research and Treatment
Oral health in cancer treatment
Publication details
- Publication date
- 31 March 2026
- Language
- EN